The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
University of Missouri-Kansas City, Kansas City, MO, USA
Mikhail Kosiborod M.D., FACC, FAHA is a cardiologist, the Vice President of Research at Saint Luke’s Health System, Executive Director of the Cardiometabolic Centre Alliance, Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Centre of Excellence at Saint Luke’s Mid America Heart Institute, Professor of Medicine at the University of Missouri-Kansas City and the inaugural recipient of the Ben McCallister, M.D. Endowed Chair in Cardiovascular Research at Saint Luke’s Health System.
Dr Kosiborod is an internationally-recognised expert in the field of cardiometabolic disease and has authored and co-authored more than 350 peer-reviewed publications. He has conducted and led numerous national and international clinical trials, many of which have had a significant impact on treatment guidelines and clinical practice. Dr Kosiborod’s body of work has been central to the elucidation of the impact of SGLT2 inhibition in improving cardiovascular outcomes and survival in various clinical settings, perhaps one of the most important advances in clinical cardiology seen in a generation.
Duke-National University of Singapore, Singapore, Singapore
Carolyn Lam MBBS, Ph.D., FRCP, MS, FACC, FAMS, FESC is a Professor at Duke-National University of Singapore and Senior Consultant at the National Heart Centre Singapore, specialising in heart failure and is recognised globally for her expertise in heart failure with preserved ejection fraction. She is a world-renowned clinical trialist, with her work as part of the global steering committee of the PARAGON and EMPEROR-Preserved trials contributing to the first FDA-approved treatment for HFpEF to date (Entresto Wins First FDA Nod in Hard-to-Treat Type of Heart Failure [ajmc.com]) as well as the first robustly positive outcomes trial in HFpEF to date. Her leadership in the field is recognised in her appointment to the 2021 European Society of Cardiology Heart Failure Guidelines Task Force. She is a recipient of the NMRC Senior Investigator Clinician Scientist Award, Programme Lead of A*STaR’s Asian neTwork for Translational Research and Cardiovascular Trials (ATTRaCT), Principal Investigator of ASIAN-HF (multinational study across 11 Asian countries), and Executive Committee member/ lead of multiple global clinical trials.
Dr Lam has published >350 articles in journals including NEJM, JAMA, Lancet, Circulation, and European Heart Journal; and has been recognised in the Clarivate Highly cited Researcher 2021 in the field of Clinical Medicine (recognition.webofscience.com/awards/highly-cited/2021/) and as a World Expert by Expertscape’s PubMed-based algorithms (top 0.1% of scholars writing about Heart Failure over the past 10 years; Heart Failure: Worldwide - Expertscape.com). She serves as Associate Editor for Circulation and the European Journal of Heart Failure. Dr Lam is heard weekly on the global podcast “Circulation On The Run” and seen regularly on television as the Resident Doctor of “Body and Soul” by MediaCorp Singapore.
University of Toronto, Toronto, Canada
Subodh Verma M.D., Ph.D., FRCSC, FAHA, FCAHS is an internationally renowned cardiac surgeon-scientist and Professor at the University of Toronto. He is the current Canada Research Chair in Cardiovascular Surgery, having previously served as the Canada Research Chair in Atherosclerosis (2007–2017). Dr Verma is a Fellow of the Canadian Academy of Health Sciences, one of the highest national honours that recognises scholars for their promotion of health science. In 2022, Dr Verma was named a Clarivate Highly Cited Researcher in Clinical Medicine. In 2021, he was bestowed the University of Toronto Lister Prize in Surgery in recognition of his outstanding and continuing productivity of international stature. He is a past recipient of the Howard Morgan Award for Distinguished Achievements in Cardiovascular Research from the International Academy of Cardiovascular Sciences and the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery. Dr Verma is an appointee of the American Association of Thoracic Surgeons (AATS) and a member of the Royal Society of Canada College of New Scholars, Artists and Scientists.
Dr Verma’s over 500 peer-reviewed publications have earned him a Google Scholar h-index of 115 with nearly 60,000 citations. He has published extensively in highly impactful journals like the NEJM, Lancet, Nature, Circulation, European Heart Journal and JACC. He is an Associate Editor of the European Heart Journal and a Section Editor of Current Opinion in Cardiology. Dr Verma is an active contributor to Canadian clinical practice guidelines and co-authored the recently updated recommendations for atrial fibrillation, antiplatelet therapy, diabetes, and heart failure; he was also a member of the 2018 AATS consensus guidelines committee on bicuspid aortic valve-related aortopathy. Dr Verma is the current Scientific Programme Committee Chair for the Canadian Society of Cardiac Surgeons and has served in various capacities on the American Heart Association Council on Cardiovascular Surgery and Anaesthesia since 2008.
Dr Verma had/has leadership roles in multiple contemporary global heart failure trials – several of which persuaded guideline writing committees to recommend paradigm changes in how individuals who live with heart failure should be managed. He founded the CardioLink platform at St Michael’s Hospital that united cardiac surgeons from across Canada to conduct robust clinical trials to better inform on surgical decision-making pathways. CardioLink has since expanded its scope to include cardiometabolic studies. Dr Verma leads a dynamic pre-clinical and translational research team that leverages pre-clinical disease models and clinical trial-derived data to identify novel mediators of cardiometabolic diseases. His current research is centred around modulating vascular regenerative cell exhaustion to alleviate cardiometabolic risk. Dr Verma holds 2 United States patents, and his research programme is supported by national peer-reviewed grants.